

The curative effect of androgen deprivation therapy alone is insufficient in high-risk prostate cancer

Se Young Choi, MD, PhD^a, Bumjin Lim, MD, MS^b, Byung Hoon Chi, MD, PhD^a, Wonchul Lee, MD, MS^b, Jung Hoon Kim, MD, PhD^c, Yoon Soo Kyung, MD, PhD^b, Dalsan You, MD, PhD^b, Choung-Soo Kim, MD, PhD^{b,*}

Abstract

To compare the outcomes of patients with high-risk prostate cancer treated by primary radical prostatectomy (RP) and primary androgen deprivation therapy (ADT).

The study included patients with high-risk or very high-risk prostate cancer. Patients treated with definitive radiation therapy and those with clinical N1 and M1 disease were excluded. The RP group was divided into sub-cohorts of patients treated with ADT and those who received ADT after biochemical recurrence post-RP. Cancer-specific survival (CSS) and overall survival (OS) were analyzed using the Kaplan–Meier method and the Cox proportional hazards model.

The study analyzed 859 patients divided into the RP group (n = 654) and ADT group (n = 205). Castration-resistant prostate cancer was detected in 23 (3.5%) patients in the RP group and 43 (21.0%) patients in the ADT group. Mortality cases included 63 (9.6%) patients in the RP group and 91 (44.4%) patients in the ADT group. CSS ($P = .0002$) and OS ($P < .0001$) were significantly higher in the RP group than in the ADT group. In the sub-cohort, CSS did not differ significantly between the RP and ADT groups, whereas OS was significantly higher in the RP group than in the ADT group ($P < .0001$). In the multivariate analysis, primary ADT increased CSS (hazard ratio, 2.068; $P = .0498$) and OS (hazard ratio, 3.218; $P < .0001$) compared with RP.

In clinically localized high-risk prostate cancer patients, primary RP was associated with better CSS and OS than primary ADT. Comprehensive counseling in this cohort of patients will help the selection of treatment.

Abbreviations: ADT = androgen deprivation therapy, BCR = biochemical recurrence, CRPC = castration-resistant prostate cancer, CSS = cancer-specific survival, OS = overall survival, PSA = prostate specific antigen, RP = radical prostatectomy.

Keywords: androgen deprivation therapy, high-risk, localized, prostate cancer, prostatectomy

Editor: Shu-Pin Huang.

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the National Research Foundation of Korea (NRF-2019R1C1C1005170) and Asan Institute for Life Sciences, Asan Medical Center (2015–071)

Compliance with Ethical Standards:

Research involving human participants and/or animals: none.

The authors have no conflicts of interest to disclose.

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

^a Department of Urology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102 Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea,

^b Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, Republic of Korea,

^c Department of Urology, Hanil General Hospital, Seoul, Republic of Korea.

* Correspondence: Choung-Soo Kim, Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea (e-mail: cskim@amc.seoul.kr).

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Choi SY, Lim B, Chi BH, Lee W, Kim JH, Kyung YS, You D, Kim CS. The curative effect of androgen deprivation therapy alone is insufficient in high-risk prostate cancer. *Medicine* 2021;100:31(e26833).

Received: 3 December 2020 / Received in final form: 15 July 2021 / Accepted: 18 July 2021

<https://doi.org/10.1097/MD.00000000000026833>

1. Introduction

Androgen deprivation therapy (ADT) is routinely used for the management of prostate cancer of any stage in Asia.^[1] ADT is the primary treatment in approximately 50% of Korean and Japanese patients, whereas it is used in approximately 20% of patients in the USA.^[2,3] In some patients, surgery is not the primary treatment option because of the potential complications of surgery and anesthesia. ADT is associated with a low rate of bone loss and cardiovascular complications in the Japanese population, and ADT decreases mortality in this cohort compared with its outcomes in Western populations.^[4] These differences may be related to ethnicity and geography; however, the mechanism underlying the efficacy of ADT in this cohort remains unclear. To further investigate the efficacy of ADT, studies analyzing a well-defined range of patients are needed.

Risk classification could help predict patient prognosis. There are many risk criteria, including grade, stage, and prostate specific antigen (PSA) level. The National Comprehensive Cancer Network also suggests criteria for the classification of high-risk disease and the criteria were validated in clinically localized prostate cancer.^[5,6] High-risk prostate cancer can be treated with radiotherapy combined with ADT or by radical prostatectomy (RP) and lymphadenectomy. Despite these treatment options, the 5-year rate of biochemical recurrence (BCR) in high-risk prostate cancer patients is >50%.^[7] In very high-risk localized prostate cancer, the rate of metastasis is 63.1%, that of prostate cancer-related death is 37.8%, and death related to all causes occurs in

42.1% of patients after 10 years.^[8] The rate of progressive disease is high in high-risk or very high-risk prostate cancer, suggesting that single treatments are not sufficient to achieve a curative effect. Therefore, multimodal treatment strategies for high-risk prostate cancer need to be developed. However, ADT alone remains a common primary therapy for prostate cancer in Asia. Here, we compared the oncologic outcomes of primary RP and primary ADT in patients with high-risk prostate cancer.

2. Materials and methods

The present study protocol was approved by the ethical review board of our institution. Data of 859 patients with high-risk or very high-risk prostate cancer between January 2008 and December 2013 were retrospectively reviewed. According to National Comprehensive Cancer Network guidelines,^[5] the criteria for high-risk prostate cancer were T3a or higher grade or Gleason score 8 or PSA >20 ng/mL. The criteria for very high-risk prostate cancer were T3b and T4 or primary Gleason pattern 5 or more than 4 cores scoring >Gleason 8. Patients who were treated with definitive radiation therapy or had clinical N1 and M1 disease were excluded. All patients were diagnosed as prostate cancer by transrectal biopsy. Clinical data collected included age at diagnosis, body mass index, Charlson comorbidity index, PSA levels, operation type, biopsy Gleason score, clinical stage, and pathological variables. Patients were divided into 2 groups: the RP group comprised patients who underwent primary RP, and the ADT group comprised patients who received primary ADT without RP. RP included robot-assisted laparoscopic prostatectomy and retropubic RP. ADT included leuprolide (7.5 and 22.5 mg), triptorelin (11.25 mg), and goserelin (3.6 and 10.8 mg). Sub-cohort consisted of patients treated with ADT and patients who received ADT after presenting with BCR post-RP. BCR was defined as an increase of PSA >0.2 ng/mL reported twice consecutively. Castration-resistant prostate cancer (CRPC) was defined as an increase in PSA in 3 consecutive measurements taken at least 1 week apart; PSA had to be ≥2 ng/mL above the nadir value despite castrate testosterone (serum testosterone <50 ng/dL). Cancer-specific

survival (CSS) and overall survival (OS) were calculated from the date of diagnosis of prostate cancer to the date of death in the total cohort. CSS and OS were analyzed from the start of ADT to death in the sub-cohorts. CSS was attributed to progressive metastatic CRPC. The follow-up period was 58.6 months (interquartile range, 38.7–80.0 months).

The baseline clinicopathological characteristics of the patients and tumors were expressed as the mean ± standard deviation or number and percentage. Continuous variables were compared using the Student *t* test, and categorical variables were analyzed using the chi-square test. Cox proportional hazard regression was used to analyze the survival model. The survival curves were estimated using the Kaplan–Meier method with the log-rank test according to groups. All statistical analyses were performed using R (version 3.5.1; R Project for Statistical Computing, Vienna, Austria). *P* values <.05 were considered statistically significant.

3. Results

The baseline characteristics of the 859 patients in the RP (*n* = 654) and ADT (*n* = 205) groups are presented in Table 1. Significant differences between the 2 groups were observed in all variables. In the RP group versus the ADT group, the mean age was lower (68.2 ± 6.9 vs 75.9 ± 6.9 ; *P* < .001) and the mean body mass index was higher (24.8 ± 2.8 vs 23.4 ± 2.8 ; *P* < .001). The rate of patients with a comorbidity index ≤1 was higher in the RP group than in the ADT group (96.5% vs 69.3%; *P* < .001). The mean initial PSA level was lower in the RP group than in the ADT group (16.8 ± 31.6 vs 50.9 ± 156.5 ; *P* < .001). Clinical T stage and Gleason score were more favorable in the RP group, and prostate size was smaller in the RP group than in the ADT group (35.7 ± 17.3 vs 39.8 ± 20.7 ; *P* < 0.011).

Table 2 lists the post-treatment outcomes. In the RP group, 56.6% of patients had pathologic T3 disease, 6.1% had N1 disease, and 40.4% had pathologic Gleason score 8 or higher. The mean volume of the removed prostate was 31.5 ± 14.9 g. The percent tumor volume was $23.5 \pm 22.3\%$. Robotic surgery was performed in 372 cases (56.9%). The surgical margin was positive in 354 cases (54.1%) and radiotherapy was conducted in

Table 1
Baseline characteristics by treatment group.

	RP (n = 654)	ADT (n = 205)	<i>P</i>
Age, yr	68.2 ± 6.9 [64.0; 73.0]	75.9 ± 6.9 [73.0; 80.0]	<.001
Body mass index, kg/m ²	24.8 ± 2.8 [23.2; 26.4]	23.4 ± 2.8 [21.6; 25.1]	<.001
Charlson comorbidity index			<.001
≤1	631 (96.5%)	142 (69.3%)	
≥2	23 (3.5%)	63 (30.7%)	
Initial PSA value, ng/mL	16.8 ± 31.6 [5.6; 20.1]	50.9 ± 156.5 [9.4; 51.5]	<.001
Clinical T stage			<.001
T2	314 (48.0%)	91 (44.4%)	
T3a	249 (38.1%)	43 (21.0%)	
≥T3b	91 (14.0%)	71 (34.7%)	
Clinical Gleason score			.001
≤7	234 (35.8%)	48 (23.4%)	
≥8	420 (64.2%)	157 (76.6%)	
TRUS volume, cm ³	35.7 ± 17.3 [25.0; 42.0]	39.8 ± 20.7 [28.0; 45.0]	.011
NCCN risk group			<.001
High risk	500 (76.5%)	70 (34.1%)	
Very high risk	154 (23.5%)	135 (65.9%)	

[] = interquartile range, ADT = androgen deprivation therapy, NCCN = National Comprehensive Cancer Network, PSA = prostate-specific antigen, RP = radical prostatectomy, TRUS = transrectal ultrasonography.

Table 2**Post-treatment outcomes.**

	RP (n=654)	ADT (n=205)
Pathology T stage		
T2	284 (43.4%)	
T3a	234 (35.8%)	
≥T3b	136 (20.8%)	
Pathology N1 stage	40 (6.1%)	
Pathology Gleason score		
≤7	390 (59.6%)	
8	113 (17.3%)	
≥9	151 (23.1%)	
Prostate volume, g	31.5±14.9 [21.6; 37.3]	
Tumor volume (%)	23.5±22.3 [8.0; 30.0]	
Operation type		
Open	282 (43.1%)	
Robot	372 (56.9%)	
Positive surgical margin	354 (54.1%)	
Radiation therapy	113 (17.3%)	
Biochemical recurrence	281 (43.0%)	
CRPC	23 (3.5%)	43 (21.0%)
Mortality	63 (9.6%)	91 (44.4%)

□=interquartile range, ADT=androgen deprivation therapy, CRPC=castration resistant prostate cancer, PSA=prostate-specific antigen, RP=radical prostatectomy.

113 (17.3%). In the RP group, BCR occurred in 281 patients (43.0%) after a median follow-up duration of 21.9 months. CRPC was detected in 23 patients (3.5%) in the RP group and 43 patients (21.0%) in the ADT group. There were 63 mortality cases (9.6%) in the RP group and 91 (44.4%) in the ADT group.

CSS and OS were significantly higher in the RP group than in the ADT group ($P=.0002$ and $P<.0001$, respectively; Fig. 1A and B). The 5-year CSS rate was 99.1% in the RP group and 91.9% in the ADT group, whereas the 5-year OS rate was 97.1% in the RP group and 69.3% in the ADT group. In the sub-cohort, CSS did not differ significantly between the RP and ADT groups

($P=.3630$; Fig. 2A). The 5-year CSS rate was 92.4% in the RP group and 91.9% in the ADT group. The OS of the sub-cohort was significantly higher in the RP group than in the ADT group ($P<.0001$; Fig. 2B). The 5-year OS rate was 92.4% in the RP group and 69.8% in the ADT group.

Table 3 shows the results of univariate and multivariate analyses of CSS and OS. Multivariate analysis of CSS performed after adjusting for all variables showed that ADT was associated with a higher risk of death than RP (hazard ratio, 2.068; 95% confidence interval, 1.001–4.275; $P=.0498$), whereas for OS, the mortality risk was significantly higher in the ADT group than in the RP group (hazard ratio, 3.218; 95% confidence interval, 2.084–4.969; $P<.0001$).

4. Discussion

The identification of a curative treatment for localized high-risk prostate cancer remains challenging. The use of RP for the treatment of high-risk prostate cancer has increased recently.^[9] In this study, primary RP was associated with better CSS and OS than primary ADT in the high-risk cohort. The 5-year OS rates in the RP and ADT groups were 97.1% and 69.3%, respectively, which is consistent with the results of previous studies reporting 5-year OS rates of 72.6% to 95.5%.^[10] However, to the best of our knowledge, the outcomes of primary ADT in a localized high-risk cohort have not been reported in detail. According to the European Organization for Research and Treatment of Cancer 30,891 trial, T0–4 N0–2 M0 prostate cancer patients who refused local treatment or had a short life expectancy and were treated with primary ADT had 10-year CSS rates of 75% to 77%.^[11] In patients with T1–2 disease treated with primary ADT, the 5-year CSS and OS rates are approximately 92% and 62%, respectively, indicating that primary ADT fails to improve survival compared with conservative management.^[12] ADT can increase the risk of metabolic, cardiovascular, and bone complications and decrease quality of life.^[13] Therefore, in low-risk prostate cancer patients, the dose of ADT needs to be




Figure 1. Kaplan-Meier curve of cancer-specific survival (A) and overall survival (B) in the different treatment groups.




Figure 2. Kaplan–Meier curve of cancer-specific survival (A) and overall survival (B) in the different treatment groups in the sub-cohort.

carefully determined to balance the benefits of treatment against the risk of side effects. In high-risk prostate cancer, the poor antitumor effects of ADT are an issue of concern. In a localized intermediate or high-risk cohort of patients treated with primary ADT, clinical Gleason score 8 or higher and T3a were significant risk factors, and patients who had both factors showed an 8-year OS rate of 16.7%.^[14] A high Gleason score is associated with the progression of castration-resistant cells.^[15] In this study, a clinical Gleason score of ≥ 8 was a significant factor for predicting CSS and OS. Patients with risk factors may benefit from more active treatments such as RP or radiotherapy. In our study, radiotherapy was conducted on 113 patients of RP group and in univariate analysis the additional radiotherapy showed improved OS (data not shown). Therefore, active treatments could help to control the disease.

Primary tumors can trigger disease progression and metastasis, which is known as the seed and soil theory.^[16] Lindberg et al^[17] compared prostatectomy specimens with metastasis samples and confirmed their phylogenetic relationship. Primary tumors contain cancer stem cells, and circulating tumor cells from the primary tumor can have a high metastatic potential.^[16] In addition, inflammatory cytokines from the primary tumor can

promote cancer progression.^[18] The heterogeneity of prostate cancer contributes to its resistance to ADT.^[19] ADT is not a radical therapy, whereas RP attempts to eliminate cancer stem cells, cytokines, and the heterogeneity of the primary tumor. In the STAMPEDE trial, radiation therapy to the primary tumor improved OS in low-volume metastatic hormone-sensitive prostate cancer, whereas it had no effect on high-volume disease. This suggests that more active treatment to the primary tumor can be helpful before progression.

ADT can result in castration resistance within 2 to 3 years by triggering androgen receptor mutation, amplification, and the development of variants.^[20] In high-risk patients treated with primary ADT, >80% of the cohort progressed to CRPC at 5 years after the initiation of ADT.^[21] In the CHARTED and LATITUDE trials, patients treated with upfront chemotherapy and androgen receptor targeting agents had a better OS than those treated with ADT alone.^[22] Combination therapies with ADT affect multiple signaling pathways with antitumor effects,^[23] suggesting that ADT alone is insufficient to cure prostate cancer.

In the European Organization for Research and Treatment of Cancer 30,891 randomized trial, deferred ADT showed several

Table 3
Cox hazard analysis of factors affecting cancer-specific and overall survival.

	Cancer-specific survival								Overall survival							
	Univariate				Multivariate				Univariate				Multivariate			
	HR	95% CI	CI	P	HR	95% CI	CI	P	HR	95% CI	CI	P	HR	95% CI	CI	P
Age (continuous)	1.060	1.020	1.110	.0040	1.036	0.993	1.081	.1041	1.100	1.070	1.120	<.0001	1.043	1.016	1.071	.0017
Body mass index (continuous)	0.970	0.880	1.060	.4690	0.995	0.903	1.096	.9144	0.900	0.850	0.950	<.0001	0.953	0.899	1.010	.1072
Comorbidity index (≥ 2 vs 1)	1.410	0.600	3.310	.4250	0.763	0.302	1.925	.5662	3.890	2.710	5.570	<.0001	1.773	1.181	2.719	.0061
PSA (>20 vs ≤ 20)	1.600	0.930	2.770	.0900	1.153	0.631	2.108	.6427	1.680	1.220	2.310	.0010	1.110	0.781	1.577	.5612
T stage ($\geq T3$ vs $\leq T2$)	1.070	0.620	1.830	.8110	1.362	0.771	2.406	.2866	0.820	0.600	1.120	.2120	0.903	0.644	1.266	.5532
Gleason score (≥ 8 vs ≤ 7)	2.950	1.390	6.250	.0050	3.406	1.500	7.734	.0034	2.240	1.490	3.350	<.0001	1.879	1.209	2.919	.0051
Treatment (ADT vs RP)	2.720	1.570	4.720	<.0001	2.068	1.001	4.275	.0498	5.790	4.200	7.990	<.0001	3.218	2.084	4.969	<.0001

CI=confidence interval, HR=hazard ratio, PSA=prostate-specific antigen.

beneficial effects over immediate ADT regarding quality of life, cost effectiveness, and minimizing the risk of pathologic fractures.^[11] RP could delay the initiation of ADT because the use of ADT generally begins after BCR. The Kaplan–Meier curve of CSS in the sub-cohort from the start time of ADT was almost the same in the 2 groups (Fig. 2A), indicating that ADT had no effect on disease progression. However, if RP delays the start of ADT, high-risk patients may benefit from deferred ADT.

Common complications of RP include urinary incontinence and erectile dysfunction. Other complications were bladder neck obstruction, urethral stricture, fistula, deep venous thrombosis, and rectal injury in RP.^[24] However, patients treated by RP showed a low risk of urinary obstruction compared with patients in a watchful waiting with ADT group.^[25] ADT is associated with side effects that decrease quality of life, such as cardiovascular disease, bone loss, decrease of libido, and depression.^[4] In addition, ADT could result in hot flushing, anemia, and fatigue.^[24] Johansson et al.^[25] hypothesized that the psychological score associated with ADT was lower than that of RP because of the immediate consequences of RP, including a positive attitude because of the removed cancer and stronger support from family. In addition, advances in operative techniques including robotic surgery decrease the risk of early urinary incontinence and sexual dysfunction.^[26] Among long-term survivors of prostate cancer, including those suffering from complications, patients who undergo RP have a higher quality of life than those receiving other treatments.^[27] Good communication regarding tumor biology and the effects of treatment will help patients with high-risk prostate cancer select the most effective treatment.

This study had several limitations. First, this was a retrospective study, which may be associated with selection bias. There were differences in the patient characteristics between groups, and the choice of treatment may be affected by confounders such as patients' or physician's preference. This could limit the generalization of the study results. We therefore adjusted for known risk factors in the multivariate analysis. In addition, to the best of our knowledge, comparison of RP and primary ADT in a high-risk cohort is rare. Second, the next sequencing of systemic therapy after primary ADT was unknown. Although upfront chemotherapy or androgen receptor targeting agent is associated with survival benefits,^[22] the identification of new agents could have beneficial effects on the patients. However, this study was performed prior to the publication of recent reports, and the Korean insurance service does not cover new trends; therefore, the effect of next sequencing might be minimal.

5. Conclusion

In clinically localized high-risk prostate cancer patients, primary RP was associated with improved CSS and OS compared with primary ADT. The curative effect of primary ADT is insufficient in high-risk prostate cancer. Indiscriminate use of ADT without considering the benefit for patients should be discouraged even in Asian countries. Comprehensive counseling in this cohort of patients will help the selection of the proper treatment.

Author contributions

Conceptualization: Se Young Choi, Choung-Soo Kim.

Data curation: Bumjin Lim, Byung Hoon Chi, Yoon Soo Kyung.

Formal analysis: Wonchul Lee, Jung Hoon Kim, Dalsan You.

Funding acquisition: Se Young Choi.

Supervision: Choung-Soo Kim.

Writing – original draft: Se Young Choi.

Writing – review & editing: Choung-Soo Kim.

References

- [1] Hinotsu S, Namiki M, Ozono S, Akaza H. NCCN Asia Consensus Statement prostate cancer. *Jpn J Clin Oncol* 2018;48:964–5.
- [2] Kang HW, Yun SJ, Chung JI, et al. National practice patterns and direct medical costs for prostate cancer in Korea across a 10-year period: a nationwide population-based study using a national health insurance database. *BMC Health Serv Res* 2019;19:408.
- [3] Tanaka N, Fujimoto K, Hirayama A, et al. Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG data. *Jpn J Clin Oncol* 2010;40:588–92.
- [4] Cooperberg MR, Hinotsu S, Namiki M, Carroll PR, Akaza H. Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer. *BJU Int* 2016;117:102–9.
- [5] Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2019;17:479–505.
- [6] Reese AC, Pierorazio PM, Han M, Partin AW. Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. *Urology* 2012;80:1075–9.
- [7] Cooperberg MR, Cowan J, Broering JM, Carroll PR. High-risk prostate cancer in the United States, 1990–2007. *World J Urol* 2008;26:211–8.
- [8] Sondi D, Wang VM, Pierorazio PM, et al. Very-high-risk localized prostate cancer: definition and outcomes. *Prostate Cancer Prostatic Dis* 2014;17:57–63.
- [9] Weiner AB, Matulewicz RS, Schaeffer EM, et al. Contemporary management of men with high-risk localized prostate cancer in the United States. *Prostate Cancer Prostatic Dis* 2017;20:283–8.
- [10] Veeratterapillay R, Goonewardene SS, Barclay J, Persad R, Bach C. Radical prostatectomy for locally advanced and metastatic prostate cancer. *Ann R Coll Surg Engl* 2017;99:259–64.
- [11] Studer UE, Whelan P, Wimpissinger F, et al. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up. *Eur Urol* 2014;66:829–38.
- [12] Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. *JAMA* 2008;300:173–81.
- [13] Tucci M, Leone G, Buttigliero C, et al. Hormonal treatment and quality of life of prostate cancer patients: new evidence. *Minerva Urol Nefrol* 2018;70:144–51.
- [14] Matsumoto K, Hagiwara M, Tanaka N, et al. Survival following primary androgen deprivation therapy for localized intermediate- or high-risk prostate cancer: comparison with the life expectancy of the age-matched normal population. *Med Oncol* 2014;31:979.
- [15] Cocchiola R, Romaniello D, Grillo C, et al. Analysis of STAT3 post-translational modifications (PTMs) in human prostate cancer with different Gleason Score. *Oncotarget* 2017;8:42560–70.
- [16] Santoni M, Piva F, Scarpelli M, et al. The origin of prostate metastases: emerging insights. *Cancer Metastasis Rev* 2015;34:765–73.
- [17] Lindberg J, Kristiansen A, Wiklund P, Gronberg H, Egevad L. Tracking the origin of metastatic prostate cancer. *Eur Urol* 2015;67:819–22.
- [18] Nguyen DP, Li J, Yadav SS, Tewari AK. Recent insights into NF-kappaB signalling pathways and the link between inflammation and prostate cancer. *BJU Int* 2014;114:168–76.
- [19] Kato M, Placencio-Hickok VR, Madhav A, et al. Heterogeneous cancer-associated fibroblast population potentiates neuroendocrine differentiation and castrate resistance in a CD105-dependent manner. *Oncogene* 2019;38:716–30.
- [20] Chandrasekar T, Yang JC, Gao AC, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). *Transl Androl Urol* 2015;4:365–80.
- [21] Choi SY, Ryu J, You D, et al. Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification. *Int J Urol* 2019;26:62–8.

- [22] Buelens S, Poelaert F, Dhondt B, et al. Metastatic burden in newly diagnosed hormone-naïve metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial. *Urol Oncol* 2018; 36:158.e113–20.
- [23] Niu Y, Guo C, Wen S, et al. ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis. *Cancer Lett* 2018;439:47–55.
- [24] Michaelson MD, Cotter SE, Gargollo PC, et al. Management of complications of prostate cancer treatment. *CA Cancer J Clin* 2008; 58:196–213.
- [25] Johansson E, Steineck G, Holmberg L, et al. Quality of life after radical prostatectomy or watchful waiting with or without androgen deprivation therapy: the SPCG-4 randomized trial. *Eur Urol Oncol* 2018;1:134–42.
- [26] O’Neil B, Koyama T, Alvarez J, et al. The comparative harms of open and robotic prostatectomy in population based samples. *J Urol* 2016; 195:321–9.
- [27] Jeong CW, Cowan JE, Broering JM, et al. Robust health utility assessment among long-term survivors of prostate cancer: results from the cancer of the prostate strategic urologic research endeavor registry. *Eur Urol* 2019;76:743–51.